0000868278
Company
ProPhase Labs, Inc.
Pharmaceutical Preparations · PRPH
follow-on
priced
OTC
424B5
Filing Timeline
SEC EDGAR
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows 424B5 and confirms the priced prospectus.
2025-12-29 · 0001493152-25-029417
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows S-1 and confirms the priced prospectus.
2025-12-19 · 0001493152-25-028480
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows 424B5 in the pre-IPO sequence.
2025-10-21 · 0001493152-25-018819
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
2025-10-15 · 0001493152-25-018187
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
2025-10-08 · 0001493152-25-017383
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B5 and confirms the priced prospectus.
2025-10-06 · 0001493152-25-016984
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows EFFECT and confirms the priced prospectus.
2025-01-30 · 0001493152-25-004207
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows 424B5 and marks the registration effective.
2024-11-20 · 9999999995-24-003531
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows FWP and confirms the priced prospectus.
2024-11-08 · 0001493152-24-044263
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows 424B5 and confirms the priced prospectus.
2024-11-07 · 0001493152-24-044012
FWP
supplemental
Free writing prospectus
Prospectus supplement or marketing filing that often updates active offering terms.
Follows 424B5 and supplements the active offering with updated prospectus details.
2024-11-07 · 0001493152-24-044016
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows EFFECT and confirms the priced prospectus.
2021-12-29 · 0001493152-21-032689
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
2021-11-24 · 9999999995-21-004476
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
2021-11-12 · 9999999995-21-004335
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows 424B5 and marks the registration effective.
2021-06-29 · 9999999995-21-002586
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows FWP and confirms the priced prospectus.
Price $12.50 · 3,000,000 shares · Gross proceeds $35,250,000
Common Stock · Exchange Nasdaq · Ticker PRPH · Over-allotment 450,000 · Use of proceeds for working capital and general corporate purposes · Underwriters ThinkEquity, Dawson James Securities, Inc.
2021-01-20 · 0001493152-21-001400
FWP
supplemental
Free writing prospectus
Prospectus supplement or marketing filing that often updates active offering terms.
Follows 424B5 and supplements the active offering with updated prospectus details.
ProPhase Labs, Inc. is offering shares of its common stock through a preliminary prospectus supplement, highlighting its diversified operations in OTC healthcare products, dietary supplements, and diagnostic testing. The company has expanded into COVID-19 and respiratory pathogen testing via its subsidiary, ProPhase Diagnostics, and recently acquired a CLIA-accredited lab. Additional developments include the sale of its corporate headquarters, a registered direct offering, and strategic partnerships. The offering is underwritten by ThinkEquity and Dawson James Securities.
2021-01-19 · 0001493152-21-001226
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows 424B5 and confirms the priced prospectus.
Common · Exchange Nasdaq Capital Market · Ticker PRPH · Use of proceeds for working capital and general corporate purposes · Underwriters ThinkEquity, Dawson James Securities, Inc.
ProPhase Labs, Inc. is offering shares of its common stock under a prospectus supplement, with proceeds intended for working capital and general corporate purposes. The filing includes details about recent acquisitions, including a CLIA-accredited lab and a new facility in New York, as well as a registered direct offering in January 2021. The company also outlines risks related to its high-risk investment profile, management's discretion over proceeds, and lack of market for warrants.
2021-01-15 · 0001493152-21-001194
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows 424B5 and confirms the priced prospectus.
Price $10.00 · 550,000 shares · Gross proceeds $5,500,000
Shares of Common Stock · Exchange Nasdaq · Ticker PRPH · Warrants to purchase up to 275,000 shares of common stock at $11.00 per share · Use of proceeds working capital and general corporate purposes
ProPhase Labs, Inc. is offering 550,000 shares of common stock and warrants to purchase 275,000 shares at $10.00 and $11.00 per share, respectively. The offering is conducted directly to accredited investors without an underwriter, with proceeds intended for working capital. The company operates in contract manufacturing, dietary supplements, and diagnostic testing, including COVID-19 tests. No public market exists for the warrants, and the offering includes a $50,000 estimated expense.
2021-01-06 · 0001493152-21-000344
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows EFFECT and confirms the priced prospectus.
Common Stock · Exchange Nasdaq Capital Market · Ticker PRPH · Underwriters A.G.P./Alliance Global Partners
ProPhase Labs, Inc. filed a 424B5 prospectus supplement to offer up to $11,343,248 in common stock through A.G.P./Alliance Global Partners. The offering allows sales at the market or negotiated transactions, with A.G.P. acting as a sales agent. The company plans to use proceeds for working capital, acquisitions, and product development. The filing updates previous S-3 registration details from 2018, including public float calculations and underwriting terms.
2020-09-23 · 0001493152-20-018227
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
ProPhase Labs, Inc. filed an S-3 registration statement that became effective on July 5, 2018, following an earlier S-3 filing in 2015. The current filing indicates the company is registering securities for public offering, though specific details about the offering's scope or purpose are not provided in the notice of effectiveness.
2018-07-05 · 9999999995-18-001713
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
ProPhase Labs, Inc. filed an S-3 registration statement effective August 21, 2015, replacing a previous POS AM filing from July 2015. The current filing indicates the company's intent to register securities under a shelf registration, while the prior submission was a post-effective amendment.
2015-08-21 · 9999999995-15-002356
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
ProPhase Labs, Inc. received SEC effectiveness for its registration statement on July 23, 2015, following a previous effectiveness notice on June 11, 2014. The current filing uses the POS AM form, while the prior used S-3, indicating potential adjustments to the registration process.
2015-07-23 · 9999999995-15-002027
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
ProPhase Labs, Inc. filed an S-3 registration statement that became effective on June 11, 2014. This follows a previous post-effective amendment (POS AM) filed on May 29, 2014, which was part of the same registration process. The S-3 form indicates the company is seeking to register securities for potential future offerings.
2014-06-11 · 9999999995-14-001737
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
ProPhase Labs, Inc.'s registration statement became effective on May 29, 2014, following a post-effective amendment (POS AM) to its previous S-3 filing from December 12, 2012. The current filing confirms the effectiveness of the registration but does not include detailed prospectus content or material updates beyond form type and date changes.
2014-05-29 · 9999999995-14-001607
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows 424B3 and marks the registration effective.
ProPhase Labs, Inc. filed a Notice of Effectiveness for a Form S-3 registration statement on December 12, 2012, indicating the effectiveness of a securities offering. The previous filing (424B3) from 2003 pertained to The Quigley Corporation, a separate entity, and detailed a prospectus supplement for stockholder sales. No direct comparison between the two filings is evident due to differing entities and purposes.
2012-12-12 · 9999999995-12-003518
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
3,000,000 shares
Common Stock · Selling stockholders only · Use of proceeds Proceeds will go to selling stockholders, no proceeds to the company
The current filing updates the prospectus for The Quigley Corporation to include an expanded number of shares available under the 1997 Stock Option Plan, increasing from 1.5 million to 3 million shares. It also introduces a provision allowing options to expire upon termination for cause. The supplement details selling stockholders, including key executives and directors, and highlights risks associated with the offering.
2003-07-09 · 0000921895-03-000446
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
1,250,000 shares
common stock · Warrants to purchase up to 1,250,000 shares of common stock at exercise prices ranging from $6.50 to $11.50, exercisable until March 7, 2004 · Selling stockholders only · Use of proceeds Proceeds will be received by the selling stockholders, with no proceeds going to the company · Flags warrants
The current 424B3 filing supplements the prospectus for The Quigley Corporation, detailing the extension of warrant expiration dates and the addition of Gold Fund Ltd., LLC as a selling stockholder. It includes an additional 250,000 shares from Forrester Financial, LLC's warrants exercisable at $9.50, extended to March 2004. The document emphasizes risks associated with the high volatility of the stock and the company's reliance on financial consulting agreements.
2003-04-02 · 0000921895-03-000195
424B3
priced
Final prospectus
Final prospectus filed near launch with final deal terms.
First tracked pre-IPO filing for this issuer.
250,000 shares
Common · Warrants to purchase common stock at $11.50 per share, extended to March 7, 2004 · Selling stockholders only · Use of proceeds Proceeds from the sale of shares will go to the selling stockholder
ProPhase Labs, Inc. filed a 424B3 prospectus supplement extending the expiration date of warrants issued to Forrester Financial, LLC from March 7, 2003, to March 7, 2004. The supplement also records the transfer of 250,000 warrants to Gold Fund Ltd., LLC, which is not an affiliate of the company.
2003-02-27 · 0000921895-03-000090
Comparable Deals
10 comparable deals
Healthcare & BiotechLast 18 months
Only 0 strict matches; expanded to 10 using nearest neighbors.
Showing top 8 by similarity.
Aardvark Therapeutics, Inc.
AARD
same SICrecent IPO
Veradermics, Inc
MANE
same SICrecent IPO
Evommune, Inc.
EVMN
same SICrecent IPO
MapLight Therapeutics, Inc.
MPLT
same SICrecent IPO
Agomab Therapeutics NV
AGMB
same SIC grouprecent IPO
Eikon Therapeutics, Inc.
EIKN
same SIC grouprecent IPO
Caring Brands, Inc.
CABR
same SIC grouprecent IPO
Functional Brands Inc.
MEHA
same SIC grouprecent IPO
Recent News
No recent news stored for this issuer.